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• The hopes for liver transplantation have been increased by 
experience with the new immunosuppresive drug cyclosporin A. 
Optimal therapy with cyclosporin A has required steroid therapy, 
but the amounts of prednisone used have been a small fraction 
of those used in the past. 
(Arch Surg 1981 ;116:1342-1343) 
I n July 1967, liver replacement with extended patient 
survival was accomplished for the first time. That 
young recipient lived for more than a year before dying of 
metastases from a hepatoma for which she originally had 
been treated.' 
RESULTS WITH CONVENTIONAL 
IMMUNOSUPPRESSION 
The demonstration of its feasibility did not make orthop-
tic liver transplantation a widely used clinical procedure, 
and, in fact, only we' and CaIne and Williams" have 
persisted in large-scale trials. The results using conven-
tional immunosuppression with azathioprine and predni-
sone to which in our series we have added lymphoid 
depletion with antilymphocyte globulin or, more recently, 
thoracic duct drainage, have been unsatisfactory. 
Before 1976 
By early summer 1976, we had treated 111 consecutive 
patients. Thirty-one (28%) of these recipients survived for 
at least a year. Now, with follow-ups of five to 11Va years, 
13 patients have still survived. This low accrual of further 
mortality after one year has been an important stimulus to 
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persist in efforts at liver transplantation and so has the 
acceptable quality of life of many long-term survivors. 
Chronic graft rejection has been the single most common 
cause of late death." 
From 1976 to 1979 
A second series of 30 patients was compiled in the 
subsequent 18 months, ending in early 1978. Half (50%) of 
these patients survived for at least one year, and today, 
after 2% to almost four years, 13 (43%) of these patients are 
still living. It was thought that improvements in surgical 
technique (especially biliary tract reconstruction), better 
diagnosis of postoperative hepatic dysfunction, and refine-
ments in immunosuppression were responsible for the 
better results. 
In subsequently treated patients, we were unable, with 
the use of immunosuppression with azathioprine and pred-
nisone, to maintain these gains in a further series of 30 
patients (the first 23 of these patients have been described 
in detail),' Instead of using antilymphocyte globulin, many 
of these 30 patients had lymphoid depletion with thoracic 
duct drainage or Iymphapheresis. All 30 patients were 
given azathioprine and prednisone. The one-year survival 
was only 33%. Many of the early deaths in this series were 
attributable to technical or management errors as in the 
past. The complications often were not intrinsically lethal 
but became so because of the need for high-dose steroid 
therapy. 
The preoperative use of thoracic duct drainage as a 
steroid-sparing device, which had been shown to be valu-
able in cadaveric kidney transplantation,' proved impracti-
cal for conditioning of liver recipients.- The amount of 
thoracic duct lymph drained in patients with chronic liver 
disease was always large. Two patients died during prepa-
ration for transplantation because of our inability to 
manage a fluid exchange of as much as 2 L/hr. 
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NONCONVENTIONAL IMMUNOSUPPRESSION 
CuHing Edge of Kidney Experience 
By late 1979, we had concluded that no real movement of 
liver transplantation toward an acceptable risk was going 
to be possible without a drastic change in immunosuppres-
sive techniques. Such a change became possible with the 
development of cyclosporin A. The powerful immunosup-
pressive qualities of cyclosporin A were accurately delin-
eated in rodents by Borel et al. 6 To our knowledge, CaIne 
and associates were the first to use cyclosporin A in larger 
animals and humans.'·s 
When cyclosporin A became available for clinical trials in 
the United States in late 1979, we began its evaluation in 
the simple kidney transplant model. From the beginning, it 
was obvious that unless some hidden problem surfaced, 
cyclosporin A would change the face of transplantation. In 
our center, we have shown that cyclosporin A alone, even in 
doses of 15 to 20 mg/kg/day, does not consistently prevent 
rejection, that it should be combined with steroid therapy 
for optimal use, and that the proper amount of prednisone 
when cyclosporin A is used is much smaller than when 
steroids are combined with azathioprine.9 
Conceptually, we have substituted cyclosporin A for 
azathioprine in what is a modern version of the time-
honored, double-drug immunosuppression introduced in 
1962 and 1963.'0 Since we have learned that rejection 
usually can be expected, we now start steroid therapy on 
the day of an operation and reduce the dose of prednisone 
in adults by 20 or 40 mg/day until a maintenance dose of 20 
mg/day is reached (usually within five or six days). The 
amount of prednisone needed in the first three months has 
been a fraction of that, which we gave when prednisone 
was combined with azathioprine. The survival of 67 cadav-
eric kidneys transplanted from seven to 15 months ago has 
been 80%.11 The most recent report by CaIne et all2 project~ 
a one-year cadaver kidney survival of 86%. 
Cyclosporin A and Liver Transplantation 
Liver transplantation with the use of cyclosporin A was 
first reported by CaIne and colleagues." The first liver 
transplantation that we performed with the use of cyclo-
sporin A was not attempted until experience had been 
acquired with 22 cadaveric kidney graftings. Since then, 14 
orthoptic liver transplantations have been performed. 
There were two operative deaths; one death was caused by 
hemorrhage, and the other death occurred when the 
abdominal incision could not be closed despite repeated 
attempts during a 48-hour period. Of the 12 survivors who 
had operations, 11 (92%) of them were still alive after seven 
to 14 months of undergoing treatment with cyclosporin A 
and low-dose steroids. The only postoperative death was 
caused by hepatic arterial thrombosis. 
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